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Background: Chronic kidney failure is associated with many kinds of metabolic changes
caused by the kidney disease itself and by dialysis treatment. Chronic kidney disease (CKD)
and hemodialysis patients (HD) are associated with increased serum hepcidin levels, the
main regulator of iron metabolism and modulated in response to anemia, hypoxia, or
inflammation.
Objectives: To investigate the determinants of hepcidin levels in patients with CKD on
conservative treatment and in hemodialysed patients.
Subjects and methods: Thirty healthy controls, 40 patients with CKD and 54 consecutive
patients on hemodialysis were included in the study. Serum hepcidin and markers of iron
status and inflammation, glycemic status including fasting blood sugar (FBS), fasting serum
insulin (FSI), the lipid profile and renal function, all were assessed using standard labora-
tory methods. The homeostasis model assessment-insulin resistance index (HOMA-IR) was
calculated. GFR was estimated using MDRD formula.
Results: In CKD and HD patients, hepcidin was correlated to FBS, FSI, HOMA-IR and, total
protein, creatinine and ferritin. eGFR was associated with hepcidin only in HD patients. In
HD patients, the best predictors of hepcidin levels were serum ferritin, FBS and creatinine
while in CKD patients the best predictors for hepcidin levels were serum albumin,





ity. Production and hosting by Elsevier B.V. All rights reserved.
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and hepcidin levels in hemodialysed patients were significantly correlated with eGFR but it
is not considered as an independent predictor for hepcidin level in these patients.
Copyright 2014, Beni-Suef University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Chronic kidney disease is a very real and growing problem.
The total number of treated patients has markedly increased
during the last 30 years (Snyder and Pendergraph, 2005). The
cause of this may be explained by the growing percentage of
elderly people in the population as well as by technical prog-
ress and broader availability of dialysis therapy also the
increasing number of diabetic patients may be a further
important factor (Van Biesen et al., 2006).
Many kinds of metabolic changes may accompany
chronic kidney failure either caused by the kidney disease
itself or due to dialysis treatment. The accumulation or
deficit of various substances and dysregulation of metabolic
pathways may participate and combine in the pathogenesis
of these changes. Chronic kidney failure may cause deficit
of some important substances that may be caused by
increased losses during dialysis sessions, deficient intake in
the diet, impaired intestinal absorption, or disturbed syn-
thesis of some essential metabolic regulators such as
erythropoietin or active vitamin D in kidneys (Cibulka and
Racek, 2007).
Metabolic complications of chronic kidney failure and
hemodialysis include changes in acid-base balance and
changes in metabolism of proteins, carbohydrates and lipids.
Additionally, chronic kidney disease is complicated by renal
anemia, bone mineral disease, atherosclerosis and cardio-
vascular disease and oxidative stress (Cibulka and Racek,
2011). Hepcidin is a small defensin-like peptide produced
primarily by hepatocytes, also by other cells like macro-
phages. Hepcidin has antimicrobial properties and it is the
main regulator of iron metabolism that controls both the
amount of dietary iron absorbed in the duodenum and the
iron release by reticuloendothelial cells (Tsuchiya and Nitta,
2013). The expression of hepcidin is upregulated by a vari-
ety of stimuli such as inflammation and iron overload, and
downregulated by hypoxia, anemia, and iron deficiency. CKD
is associated with increased serum hepcidin levels that may
contribute to the development and severity of anemia and to
resistance to erythropoiesis-stimulating agents. Elevated
serum hepcidin levels contribute to the dysregulation of iron
homeostasis in CKD patients (Tsuchiya and Nitta, 2013).
Treatment with agents that lower serum hepcidin levels or
inhibit its actions may be an effective approach for restoring
normal iron homeostasis and improving anemia in CKD pa-
tients. The aim of this article was to investigate first, the
correlation of hepcidin levels with the glycemic status, lipid
profile, inflammatory status, and iron status in patients with
CKD on conservative treatment and in hemodialysed pa-
tients. Second, the predictors of hepcidin level in these
patients.2. Subjects and methods
2.1. Subjects
The study included thirty healthy controls, 40 consecutive
patients with CKD who visited the outpatient Nephrology
clinic of different hospitals in Taif, KSA, to ensure coverage of
the full GFR range and 54 consecutive patients on hemodial-
ysis, using a biocompatible Fresenius Polysulfone R dialysis
membrane. These patients did not receive intravenous iron or
erythropoietin (EPO) during dialysis. Relevant clinical and
biochemical data were retrieved from the patients' records.
Inclusion criteria for the maintenance hemodialysis pa-
tients were the initiation of maintenance hemodialysis  6
months (three times per week for 4e5 h per session) prior the
study and a baseline hemoglobin (Hb) level > 10 g/dl.
Exclusion criteria were the previous treatment with
immunosuppressive drugs, active inflammatory disease,
clinical signs of acute infection, liver disease, anymalignancy,
evidence of blood loss gastrointestinal bleeding, trauma, etc.
Healthy controls had to have no clinical or laboratory evidence
of any chronic disease. The study was approved by all partici-
pants gave informed consent and the study followed the rules
of the National Medical Committee for Medical and Bioethics.
Thorough clinical examination including waist circumference
height, weight, BMI is also calculated asweight in kg/(height in
meters)2. Blood pressure measurement was done using
manual sphygmomanometer. Mean arterial blood pressure
(MAP) was also calculated. MAP ¼ [(2  diastolic) þ systolic]/3.2.2. Sampling
In hemodialysis patients, blood samples were collected at the
start of hemodialysis. Peripheral blood sampleswere collected
midweek from maintenance hemodialysis patients, after an
overnight fast, immediately before and after a single session
of hemodialysis. The samples were put into pyrogen-free
tubes containing clot activator (without anticoagulant). After
coagulation, samples were centrifuged (at 1500  g for 15 min)
and serumwas harvested, aliquoted and stored at70 C until
analysis. For healthy control subjects, and chronic kidney
disease, blood was also drawn from a peripheral vein after an
overnight fast.2.3. Methods
Serumhepcidin levels weremeasured using the commercially
available human hepcidin C-ELISA kit (Cusabio Biotech,
Wuhan, China) according to the manufacturer's instructions.
Fasting blood sugar (FBS), Total cholesterol (TC), triglycerides
(TG), hemoglobin (Hb), hematocrit (Ht), total protein, albumin,
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nine, blood urea, iron, ferritin, total iron-binding capacity
(TIBC) were assayed using Synchron CX-9 (Instruments Inc.;
Scientific Instruments Division, Fullerton, CA 92634, 3100,
USA.) system auto analyzer applying enzymatic colorimetric
method (interassay CVs < 3%). Insulin was assayed by Micro-
particle Enzyme Immunoassay (MEIA) on the AxSYM (Abbott
Ireland, Diagnostic Division-Lisnamuck, Longford Co., Long-
ford, Ireland þ353-43-31000) for the quantitative determina-
tion of insulin in human serum or plasma. The homeostasis
model assessment-insulin resistance index (HOMA-IR): It was
calculated using the equation: HOMA-IR ¼ fasting glucose
(mg/DL)  fasting insulin (mU/ml) ÷ 405. The cutoff point to
define insulin resistance corresponds to HOMA-IR  3.8
(Shirai, 2004). The glomerular filtration rate was estimated
(eGFR) by the simplified Modification of Diet in Renal Disease
formula (Levey et al., 1999). GFR in Saudi
patients ¼ 1.86  (Scr)1.154  (age)0.203  .742 (if patient is
female) (Al Wakeel et al., 2009).3. Statistical analysis
Data are expressed as the mean ± SD. Each variable was
assessed for a normal distribution. Using the Kolmogor-
oveSmirnov test. Statistical differences between the groups
were identified using one-way analysis of variance (ANOVA)
followed by post-test. Pearson's correlation test was per-
formed to determine the relationships between serum hep-
cidin levels and study variables. Multiple linear step-wise
regression analysis with hepcidin as a dependent variable was
performed to identify the risk factors which determined its
level. All statistical results were based on two-sided tests.
Data were analyzed using Package for Social Sciences (SPSS)
software for Windows (version 12.0; SPSS Inc., Chicago, IL,
USA). p < .05 was regarded as significant.4. Results
There was an insignificant (p > .05) difference in age between
the study groups while, BMI was significantly (p < .05) higher
in patients with CKD compared to control and HD groups.Fig. 1 e Serum hepcidin level in different groups, it was
significantly higher (p < .001) in CKD and HD groups
compared to control groups. HD patients had a
significantly higher (p < .01) hepcidin than CKD patients.4.1. Glycemic status
Both CKD and HD patients had significantly (p < .001) higher,
fasting blood sugar, fasting serum insulin, HOMA-IR when
compared to normal subjects. All these parameters were
significantly higher in HD patients than in CKD patients
(p < .05, p < .01, p < .05 respectively).
4.2. Lipid profile
Cholesterol and triglycerides were significantly (p < .001)
higher in both patient groups compared to normal group.
Moreover, triglycerides was significantly (p < .01) higher in HD
patients than that of CKD patients.
4.3. Inflammatory markers
Fibrinogen and hsCRP are significantly higher in CKD (p < .001,
p < .01 respectively) and HD (p < .001, p < .001 respectively)
patients compared to control subjects. Moreover, these two
parameters were significantly (p < .05, p < .01 respectively)
higher in HD patients compared to CKD patients. Total protein
and albumin were significantly lower in both patient groups
compared to normal group with no significant difference was
found between the two patient groups.
4.4. Renal function
Both CKD and HD patients had significantly higher (p < .001)
creatinine and urea when compared to control subjects, with
significantly higher (p < .01) result in HD patients compared to
CKD patients. HD patients had significantly lower (p < .01)
eGFR compared to CKD patients. Moreover, both patient
groups had significantly lower (p < .001) eGFR than that of
normal group.
4.5. Hepcidin and iron status
Hepcidin (Fig. 1) and ferritin (Table 1) are significantly higher
(p < .001) in CKD patients and in HD patients compared to
control subjects with being significantly higher in HD patients
compared to CKD patients. Hb, iron and TIBC were signifi-
cantly lower (p < .001) in CKD patients and HD patients
compared to control subjects. Also, Ht was significantly lower
(p < .01) in CKD patients and HD patients than that of control
subjects. Iron was significantly higher (p < .01) in HD patients
than in CKD patients but TIBC and Ht were significantly lower
in HD patients than in CKD patients with no significant dif-
ference was found between the two patient groups regarding
Hb level (Table 1).
4.6. Correlation study
The association between studied variables had been tested by
Pearson's correlation coefficient with p-values < .05 was
considered as statistically significant (Table 2). In CKD and HD
patients, hepcidin was associated with the glycemic status
parameters, also with total protein, creatinine and ferritin. In
CKD patients only, hepcidin was correlated to cholesterol and
Table 1 e Biochemical characteristics of the investigated groups.
Characteristics Control (n ¼ 30) CKD (n ¼ 40) HD (n ¼ 54)
Gender 16m, 14f 26m, 14f 27m, 27f
Age (years) 45.10 ± 2.67 43.60 ± 4.27 43.35 ± 5.08
BMI (kg/m2) 24.40 ± 3.93 26.65 ± 4.66* 24.91 ± 5.84#
Fasting blood sugar (mg/dl) 82.07 ± 8.9 113.33 ± 9.39*** 120.95 ± 10.2***#
Fasting plasma insulin (IU/dl) 5.73 ± 3.31 7.98 ± 2.3** 11.30 ± 4.31***#
HOMA-IR 1.15 ± .51 2.25 ± .97** 3.98 ± 1.73***#
Cholesterol (mg/dl) 179.10 ± 10.79 201.10 ± 14.06*** 209.35 ± 13.52***
Triglycerides (mg/dl) 102.30 ± 14.68 163.90 ± 14.01*** 183.07 ± 12.79***##
Total protein (g/dl) 7.47 ± 2.16 6.30 ± 2.43* 6.48 ± 2.19*
Albumin (g/l) 4.53 ± 1.28 3.37 ± 1.34* 3.48 ± 1.18*
Fibrinogen (mg/dl) 227.50 ± 22.10 309.50 ± 26.50*** 342.33 ± 36.62***#
hsCRP (mg/dl) 1.39 ± .45 3.35 ± 1.24** 6.94 ± 2.22***##
GFR (ml/min) 99.40 ± 11.65 30.27 ± 7.10*** 8.69 ± 3.89***##
Creatinine (mg/dl) .91 ± .12 6.22 ± 2.64*** 13.20 ± 4.99***##
Urea (mg/dl) 22.59 ± 6.30 84.35 ± 11.07*** 139.69 ± 27.59***##
Hb (g/dl) 14.36 ± 3.53 9.89 ± 4.95*** 10.06 ± 4.56***
Ht (%) 44.10 ± 9.40 33.44 ± 7.69** 30.02 ± 5.17**#
Iron (mg/ml) 96.70 ± 7.58 56.85 ± 8.53*** 80.26 ± 11.04***##
TIBC (mg/ml) 363.60 ± 46.48 256.60 ± 45.54*** 232.48 ± 32.14***#
Ferritin (mg/dl) 55.80 ± 7.49 124.83 ± 14.03*** 698.80 ± 74.04***##
HD ¼ hemodialysis, CKD ¼ chronic renal failure, m; male, f; female. Data given are mean ± SD.
*p < .05, **p < .01, ***p < .001 vs control, #p < .05, ##p < .01 CKD vs HD.
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with GFR, Hb and TIBC.Table 2 e Correlation of hepcidin with the measured
parameters in CKD and HD groups.4.7. Stepwise regression analysis
Stepwise regression analysis of CKD patients showed that the
best predictors for hepcidin levels in this group were serum
albumin, cholesterol and HOMA-IR as they account for 83.9%
of the variance in the level of hepcidin in this group (Table 3)
(F ¼ 68.69, p ¼ .000). Moreover, regression analysis of HD pa-
tients showed that the best predictors for hepcidin levels in
this group were serum ferritin, FBS and creatinine as they
account for 58.1% of the variance in the level of hepcidin in
this group (Table 4) (F ¼ 25.527, p ¼ .000).
Parameter CKD HD
R p R p
Age .248 NS .165 NS
BMI .231 NS .040 NS
Fasting blood sugar .656** .000 .616** .000
Fasting plasma insulin .593** 000 .417* .002
HOMA-IR .633** .000 .483* .000
CHOLE .450** .004 .138 NS
TG .291 NS .099 NS
Tptn .886** .000 .321* .018
Albumin .894** .000 .106 NS
Fibrinogen .250 NS .155 NS
CRP .048 NS .057 NS
Creatinine .827** .000 .521** .000
GFR .283 NS .404* .002
Urea .232 NS .090 NS
Hb .176 NS .291* .033
Ht .310 NS .161 NS
Iron .052 NS .149 NS
TIBC .262 NS .388* .004
Ferritin .416* 008 .672** .000
*Correlation is significant at the .05 level (2-tailed).
**Correlation is significant at the .01 level (2-tailed).5. Discussion
In both patient groups, hepcidin was correlated to fasting
blood sugar, fasting plasma insulin, HOMA-IR, total protein,
creatinine, ferritin. But it was correlated to cholesterol and
albumin in CKD patients only and to GFR, Hb and TIBC in HD
group not in CKD patients. Moreover, regression analysis in
these patients showed that the best predictors for hepcidin
levels in this group were serum ferritin, FBS and creatinine as
they account for 58.1% of the variance in the level of hepcidin
in this group. Stepwise regression analysis in CKD patients
showed that the best predictors for hepcidin levels in this
group were serum albumin, cholesterol and HOMA-IR as they
account for 83.9% of the variance in the level of hepcidin in
this group. Abnormalities of carbohydrate metabolism are
very common in patients with chronic kidney failure.
Impaired glucose tolerance occurs together with the loss of
kidney function (Alvestrand, 1997). Insulin resistance is pri-
marily obvious when GFR is below 50 ml/min. Reducedinsulin-mediated non-oxidative glucose disposal is the most
marked defect of glucose metabolism, but impairments of
glucose oxidation, the defective suppression of endogenous
glucose production, and abnormal insulin secretion also
contribute to uremic glucose intolerance. Accumulation of
nitrogenous uremic toxins appears to be the leading cause of a
specific defect in insulin action. The consequences of chronic
kidney failure, such as exercise intolerance, metabolic
acidosis, anemia, secondary hyperparathyroidism, or inade-
quate activation of vitamin D also indirectly play a role
Table 3 e Regression analysis in CKD patients.
Coefficientsa
Model Unstandardized coefficients Standardized coefficients t Sig.
B Std. error Beta
1 (Constant) 67.830 2.852 23.786 .000
Albumin 10.377 .842 .894 12.324 .000
2 (Constant) 104.320 15.405 6.772 .000
Albumin 9.710 .841 .837 11.552 .000
CHOLE .170 .071 .174 2.406 .021
3 (Constant) 112.771 14.891 7.573 .000
Albumin 8.125 1.025 .700 7.926 .000
CHOLE .210 .069 .215 3.067 .004
HOMA 2.190 .903 .202 2.426 .020
a Dependent variable: hepcidin.
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additional aspect of the insulin/glucose-like regulation of
serum iron concentrations, namely, hepcidin, in response to
glucose. Furthermore, cell culture experiments suggest that
the pancreatic b-cell may serve as the common source of both
insulin and hepcidin after glucose absorption from the gut.
These findings suggest that glucose, likely by triggering the
release of hepcidin from pancreatic b-cells, may represent a
novel regulator of serum iron concentrations.
Hepcidin and ferritin are significantly higher in chronic
kidney disease patients and in hemodialysed patients
compared to control subjects. Also, Malyszko et al. found that
in their study on patients with chronic renal failure and
hemodialyzed patients, serum, ferritin and hepcidin were
significantly higher than in the healthy volunteers. Our study
agrees with the study of Peters et al., on hemodialysis patients
who exhibited significantly higher hepcidin-25 levels than
patients with CKD. Peters et al., revealed that, serum
hepcidin-25 levels decreased only slightly during hemodialy-
sis (10e15%), thismay be explained as ultrafiltrationmay have
resulted in more concentrated levels of hepcidin-25 and a
minor underestimation of hepcidin clearance. Our data also
agree with some studies reporting higher hepcidin levels in
HD patients (Ashby et al., 2009; Tomosugi et al., 2006). How-
ever, our present data disagree with the results of Pelusi et al.,




1 (Constant) 127.631 15.989
Ferritin .150 .023
2 (Constant) 116.601 15.071
Ferritin .107 .025
FBS .338 .104




a Dependent variable: hepcidin.significantly different between the whole group of chronic
hemodialysis patients (CHD) patients and controls. The failure
to confirm a relative hyper-hepcidinemia in the overall CHD
group could be explained by a number of reasons such as, the
inclusion of a large and less selected CHD population
compared to previous studies, including those requiring high
doses of Epo and with relative iron deficiency (factors both
known to reduce hepcidin), also, the relatively low average
iron stores in this cohort as reflected bymedian serum ferritin
levels of only 265 ng/ml (Pelusi et al., 2013). The elevated levels
serum hepcidin in patients with renal failure, may reflect an
underlying inflammatory state associated with advanced
renal failure, loss of kidney function, and development of
anemia of chronic disease, the thing that was obvious in the
present study in the form of high fibrinogen and hsCRP in
chronic kidney disease patients and hemodialysed patients
but we could not find a significant correlation between hep-
cidin and either fibrinogen or hsCRP. CKD is associated with a
chronic imbalance of prooxidant and antioxidant factors that
results in a state of chronic inflammation. Oxidative stress
induces both insulin resistance by decreasing internalization
of insulin (Bertelsen et al., 2001) and increased ferritin syn-
thesis. Free radicals originate from leucocytes, which are
activated during the contact with the dialysis membrane, and
also from erythrocyte iron released as a consequence of he-
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chestrates the cellular defense against stress and inflamma-
tion (Torti, and Torti, 2002). In some patients with chronic
renal failure, on conservative treatment and on dialyses,
functional iron deficiency is present which is characterized by
the presence of adequate iron stores with serum ferritin level
is either normal or elevated. In addition, inflammatory iron
block occurs among these patients due largely to an under-
lying inflammatory state and both functional deficiency and
inflammatory block cause elevated ferritin level (Malyszko
et al., 2006). Hepcidin in the present study in the two groups
of patients, was related to ferritin that agrees with the results
of Peters et al., who revealed that serum ferritin concentration
was a significant predictor of hepcidin-25 levels in multiple
regression analysis. However, Malyszko et al., could not find
significant correlations between hepcidin and ferritin in pa-
tients with chronic renal failure on conservative treatment
and on hemodialyses. In addition, Kulaksiz et al. (2004),
described no correlation between hepcidin and ferritin was
observed in their study on hemodialyses patients. However,
Peters et al., revealed that serum ferritin concentration was a
significant predictor of hepcidin-25 levels in multiple regres-
sion analysis. Similar correlation between ferritin and hepci-
din was reported by Dallalio et al., in anemic patients
undergoing diagnostic bone marrow examination. In our
studywe observed that in the two groups of patients hepcidin,
was related to total protein and creatinine but not correlated
with iron. Our results agree with the results of Malyszko et al.,
who revealed that in patients with chronic renal failure,
hepcidin was correlated significantly in univariate analysis,
with total protein, and creatinine but not with iron. Taes et al.
(2004), reported that hepcidin accumulates in renal insuffi-
ciency on the basis of hepcidin correlations with Cr-EDTA
clearance rate, creatinine clearance rate, and serum creati-
nine. Kulaksiz et al., suggested that kidneys, besides the liver,
may participate in the hepcidin elimination as well. They re-
ported that hepcidin was produced as an intrinsic peptide in
the epithelial cells of the tubule and collecting duct in
mammalian kidney and might be released luminally into the
urine (Dallalio et al., 2003). Our present data revealed that
creatinine was in correlate to hepcidin partly support this
hypothesis. The present study revealed that hepcidin, was
related to albumin in the CKDpatients but not in hemodialysis
patients which was consistent with the results of Malyszko
et al., who revealed that in patients with chronic renal failure,
hepcidin correlated significantly in univariate analysis, with
albumin. Hepcidin in the present study, was related to GFR in
hemodialysis but not in the CKD patients. These findings
disagree with the studies of Kuan et al. (2005), and Dallalio
et al., where, the independent effect of eGFR on hepcidin
levels was not evaluated in their study but agrees with the
results of Ashby et al., who reported that hepcidin levels in
their patients were significantly correlated with eGFR. Peters
et al., also could not find a correlation between hepcidin-25
and eGFR. The authors explained this finding by the hypoth-
eses that hepcidin-25 differs from other LMWproteins such as
b2-microglobulin or cystatin-C. They postulated that hepcidin
bind to a large carrier protein that prevent it to be freely
filtered. Nevertheless, their additional studies were inconsis-
tent with such a hypothesis. Primarily, the estimated hepcidinclearance was compatible with the expected clearance of a
freely filterable protein of similar molecular mass. Second-
arily, the arterio-venous difference in hemodialysis patients
suggests that hepcidin-25 is handled similar to other LMW
proteins. However, they were unable to estimate the relative
role of ultrafiltration and of sticking to the membrane of the
artificial kidney. In view of the fact that blood samples were
not taken until after the start of hemodialysis, it is difficult to
exclude an immediate effect of hemodialysis on serum hep-
cidin levels, so far, it seems improbably that hepcidin levels
are significantly affected by hemodialysis in this little period
of time (Peters et al., 2009).
In conclusion, in CKD and HD patients, hepcidin was
associated with the glycemic status parameters, also with
total protein, creatinine and ferritin. Hepcidin was correlated
to cholesterol and albumin only in CKD patients. However,
hepcidin was correlated with GFR, Hb and TIBC in HD patients
but they were not considered as independent predictors for
hepcidin level in these patients. Serum albumin, cholesterol
and HOMA-IR are the best predictors for hepcidin levels in
CKD patients as they account for 83.9% of the variance in
hepcidin level in this group. Moreover, in HD patients the best
predictors for hepcidin levels in this group were serum
ferritin, FBS and creatinine as they account for 58.1% of the
variance in the level of hepcidin in this group. So if we can
control the glycemic status in these patients we can adjust the
level of hepcidin and if we can decrease the level of hepcidin
we can control the anemia in the chronic diseases.r e f e r e n c e s
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